AMAGINE-2 Phase III extension study shows two year positive results for Siliq (brodalumab injection) as a treatment of psoriasis.- Ortho Dermatologics.

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced results from the pivotal Phase III long-term extension study (AMAGINE-2), which demonstrated that Siliq (brodalumab) injection provided sustained high levels of skin clearance (PASI 100) over more than two years in patients with moderate-to-severe psoriasis. These findings are being presented for the first time at the 2017 Fall Clinical Dermatology Conference in Las Vegas.

Over a two-year trial, a PASI 100 response rate was reached by 59 percent of a sub-analysis group of patients, demonstrating that Siliq is a long-term option to treat moderate-to-severe psoriasis which is highly important as patients always fear aflare-up of their psoriasis after initial clearing.

Comment: More than 65 percent of both ustekinumab-na�ve and -experienced patients in AMAGINE-1 receiving Siliq treatment experienced complete clearance (PASI 100) at week 52, making this an excellent solution with proven results for a wide range of patients with moderate-to-severe psoriasis.